The UK and US have agreed to a key trade agreement that will guarantee no levies on British medicine shipments entering the American market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to raise expenditure on medicines through the NHS. This pledge secures that import taxes on these key goods will be held at nothing for a timeframe of three years.
This development comes after previous warnings to hike duties on branded drug imports, with figures mentioned up to double the cost.
"This arrangement with the United Kingdom reinforces the worldwide climate for cutting-edge drugs and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," a statement noted.
Commercial Significance
Pharmaceuticals are one of the the United Kingdom's most significant export categories to the America, which is clearly the largest destination for major British pharmaceutical firms.
Export figures reveal that in the 12 months leading up to last September, the UK sold medicines totaling over eleven billion pounds to the US. This value represented nearly one-fifth of total UK exports in that timeframe.
"This deal protects work, boosts funding and facilitates the UK to become a worldwide center for medical research," a government official commented.
Specific NHS Changes
The pact includes several key pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to double overall health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount manufacturers must refund to the NHS to prevent overspending will be restricted at 15%. Previously, repayments were more than twenty percent.
Recent Tensions
The deal comes amid a long-running row between the sector and the ministers over medicine costs and NHS adoption.
The disagreement were heightened by arguments that American customers were paying several times more for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been pledged toward US facilities.
A senior figure stated that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had declined as a percentage of its total funding over the past decade.
